GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iCo Therapeutics Inc (GREY:ICOTF) » Definitions » EV-to-EBITDA

iCo Therapeutics (iCo Therapeutics) EV-to-EBITDA : -8.31 (As of Apr. 27, 2024)


View and export this data going back to 2009. Start your Free Trial

What is iCo Therapeutics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, iCo Therapeutics's enterprise value is $8.89 Mil. iCo Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2021 was $-1.07 Mil. Therefore, iCo Therapeutics's EV-to-EBITDA for today is -8.31.

The historical rank and industry rank for iCo Therapeutics's EV-to-EBITDA or its related term are showing as below:

ICOTF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -12.31   Med: -0.51   Max: 0.29
Current: -12.31

During the past 13 years, the highest EV-to-EBITDA of iCo Therapeutics was 0.29. The lowest was -12.31. And the median was -0.51.

ICOTF's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.14 vs ICOTF: -12.31

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-27), iCo Therapeutics's stock price is $1.1693. iCo Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2021 was $-0.375. Therefore, iCo Therapeutics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


iCo Therapeutics EV-to-EBITDA Historical Data

The historical data trend for iCo Therapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iCo Therapeutics EV-to-EBITDA Chart

iCo Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -45.13 -39.99 -49.82 -126.42 -123.95

iCo Therapeutics Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -48.22 -66.67 -88.16 -123.95 -275.03

Competitive Comparison of iCo Therapeutics's EV-to-EBITDA

For the Biotechnology subindustry, iCo Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iCo Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, iCo Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where iCo Therapeutics's EV-to-EBITDA falls into.



iCo Therapeutics EV-to-EBITDA Calculation

iCo Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=8.893/-1.07
=-8.31

iCo Therapeutics's current Enterprise Value is $8.89 Mil.
iCo Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iCo Therapeutics  (GREY:ICOTF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

iCo Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.1693/-0.375
=At Loss

iCo Therapeutics's share price for today is $1.1693.
iCo Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.375.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


iCo Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of iCo Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


iCo Therapeutics (iCo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
777 Hornby Street, 6th Floor, Vancouver, BC, CAN, V6Z 1S4
iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between the cells of the immune system. Geographically, it operates in Canada and Australia.

iCo Therapeutics (iCo Therapeutics) Headlines

No Headlines